Attorney Articles
THC, CBD, and the FDA: What to Expect at the Federal and State Level
April 18, 2019 - mg Magazine
Ian Stewart (Partner-Los Angeles) published “THC, CBD, and the FDA: What to Expect at the Federal and State Level” in the April 18, 2019, edition of mg Magazine. Ian and Genese point out that the expectation that the FDA will liberalize its position on CBD comes at a time when the agency is preparing to take a more aggressive stance on regulating the dietary supplement industry. “One should expect the FDA to maintain a fairly consistent position that CBD and other cannabinoids must follow the scientific process like any other chemical component, which will take many months at the minimum,” they say. “Until then, vigilance is required.”